Is the immune response a friend or foe for viral therapy of glioma?

Neuro Oncol. 2017 Jul 1;19(7):882-883. doi: 10.1093/neuonc/nox082.

Authors

Hideho Okada¹, Stephen H Thorne¹

Affiliation

¹ Department of Neurological Surgery and the Cancer Immunotherapy Program, University of California San Francisco, San Francisco,California; The Parker Institute for Cancer Immunotherapy,San Francisco,California; Western Oncolytics Ltd, Pittsburgh, Pennsylvania; Department of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.

No abstract available

Publication types

Comment

MeSH terms

Genetic Therapy
Genetic Vectors
Glioma*
Humans
Neoplasm Recurrence, Local
Oncolytic Virotherapy*